Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CSTB |
| Gene Name: | CSTB |
| Protein Full Name: | Cystatin-B |
| Alias: | CPI-B; CST6; Cystatin B; CYTB; EPM1; Liver thiol proteinase inhibitor; PME; Stefin B; Stefin-B; STFB |
| Mass (Da): | 11140 |
| Number AA: | 98 |
| UniProt ID: | P04080 |
| Locus ID: | 1476 |
| COSMIC ID: | CSTB |
| Gene location on chromosome: | 21q22.3 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR (no mutation found) |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.05 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | CSTB is a cysteine protease inhibitor which can reversibly inhibit papain and cathepsins L/H/B. Its role in cancer progression is unclear. Its expression has been noted to increase in many cancers such as lung, breast, head and neck, and prostate. High expression of CSTB may decrease apoptosis, and knockout mice displayed significantly lower metastatic spread. However, higher levels of the protein has also been shown to correlate witha favourable prognosis of cancer patients. Enhanced expression may decrease tumor-associated proteolytic activity and suppressor cancer. |